Non-Hodgkin Lymphoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (B-cell Lymphomas, T-cell Lymphoma), By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels), By Region and Competition, 2020-2030F

Market Overview

The Global Non-Hodgkin Lymphoma Market, valued at USD 7.24 Billion in 2024, is projected to experience a CAGR of 7.72% to reach USD 11.31 Billion by 2030. The global Non-Hodgkin Lymphoma market comprises a comprehensive array of diagnostic tools and therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies such as CAR T-cell therapy, radiation, and stem cell transplantation, tailored for various lymphoma subtypes. Market growth is primarily driven by the increasing global incidence of Non-Hodgkin Lymphoma and a rising preference for advanced treatment modalities like targeted therapies and immunotherapies. Furthermore, technological advancements in molecular diagnostics and continuous innovation in treatment approaches contribute significantly to market expansion.

According to the International Agency for Research on Cancer (GLOBOCAN 2022), a total of 553,389 new cases of Non-Hodgkin Lymphoma were reported globally in 2022. This growing disease burden necessitates ongoing market development. However, a significant challenge impeding market expansion remains the substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments. These high costs limit patient access and pose considerable financial burdens on healthcare systems worldwide.

Key Market Drivers

The Global Non-Hodgkin Lymphoma market is significantly propelled by sustained advancements in targeted therapies and immunotherapies, which offer enhanced treatment efficacy and improved patient outcomes. The continuous development of novel agents specifically designed to target molecular pathways implicated in lymphoma pathogenesis has expanded therapeutic options, particularly for patients with relapsed or refractory disease. For instance, according to Genmab, on June 26, 2024, the FDA approved epcoritamab-bysp, known as EPKINLY®, for relapsed or refractory follicular lymphoma, representing the first and only T-cell engaging bispecific antibody administered subcutaneously for this indication. This progress not only provides new lifelines for patients but also fuels market expansion through the introduction of premium-priced, innovative treatments.

Complementing these therapeutic breakthroughs are the growing research and development initiatives across the pharmaceutical and biotechnology sectors, which are crucial for identifying new drug candidates and refining existing treatment protocols. Increased investment in understanding the heterogeneous nature of Non-Hodgkin Lymphoma subtypes and developing personalized medicine approaches accelerates the pace of innovation. According to the Lymphoma Research Foundation, in 2024, it awarded 28 research grants totaling over $3.5 million to scientists at leading cancer research institutions, specifically for innovative lymphoma and chronic lymphocytic leukemia research. These concerted efforts by academic institutions, industry players, and advocacy groups underpin a robust pipeline of investigational drugs. Such dedicated research is essential given the substantial patient population, with an estimated 80,350 people projected to be diagnosed with Non-Hodgkin Lymphoma in the United States in 2025, according to the American Cancer Society. This ongoing commitment to scientific discovery directly contributes to market dynamism by continually introducing new therapies and diagnostic tools.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with novel therapeutics, particularly advanced biologics and CAR T-cell treatments, presents a significant impediment to the growth of the global Non-Hodgkin Lymphoma market. These high expenditures directly limit patient access to potentially life-saving interventions, especially in healthcare systems with constrained budgets or in regions lacking robust insurance frameworks.

According to the American Society of Clinical Oncology (ASCO), in 2023, the list prices for CAR T-cell therapies approved for certain lymphoma subtypes ranged from $373,000 to $475,000 per patient for the drug product alone, excluding significant associated hospital and administrative costs. This considerable financial burden often necessitates rigorous approval processes and restricts broader adoption, consequently decelerating market expansion despite the evident clinical benefits of these advanced modalities. Healthcare providers and payers worldwide face immense pressure to manage these substantial costs, which in turn impacts the availability and uptake of these innovative treatments.

Key Market Trends

The non-Hodgkin lymphoma market is significantly influenced by the accelerating shift towards personalized medicine, primarily propelled by advanced genomic profiling. This trend emphasizes tailoring treatments based on an individual patient's unique genetic makeup, leading to more targeted and effective therapeutic interventions. For instance, the European Hematology Association's (EHA) guidelines for large B-cell lymphomas and peripheral T-cell lymphomas in 2025 highlight the increasing cruciality of molecular profiling for accurate diagnosis and subtype identification, which directly informs personalized treatment strategies. The expedited delivery of such critical diagnostic information is further advanced, as exemplified by the FDA approval of Thermo Fisher Scientific's Oncomine Dx Express Test in September 2025, designed for companion diagnostics and tumor profiling with results available in as little as 24 hours. This capability enables faster and more precise treatment decisions, enhancing patient outcomes and driving market expansion for advanced diagnostic solutions.

Concurrently, the application of artificial intelligence (AI) in diagnostics and therapy optimization represents another transformative trend. AI algorithms are increasingly utilized to analyze complex patient data, improve diagnostic accuracy, predict treatment responses, and streamline drug discovery processes in non-Hodgkin lymphoma. The European Society for Medical Oncology (ESMO) acknowledges this significant impact, with its planned ESMO AI and Digital Oncology Congress in 2025 dedicated to exploring how AI is actively transforming cancer diagnosis, treatment, and management. Companies like Absci are at the forefront of this integration; in August 2024, Absci partnered with Memorial Sloan Kettering Cancer Center to develop novel cancer therapeutics using AI-driven drug discovery platforms, demonstrating the tangible impact of AI in accelerating the development of innovative treatments. This strategic integration of AI enhances efficiency across the oncology care continuum, contributing to market growth through improved therapeutic selection and expedited drug development.

Segmental Insights

The T-cell Lymphoma segment is experiencing rapid growth within the Global Non-Hodgkin Lymphoma Market, primarily driven by significant advancements in the molecular and genetic characterization of T-cell lymphomas, which has enhanced the understanding of disease biology and pathogenesis. This accelerated growth is further fueled by the introduction of novel targeted therapies and immunotherapies, including antibody-drug conjugates and emerging agents in clinical pipelines, offering more precise and effective treatment options beyond conventional chemotherapy. Additionally, increasing research and development activities by pharmaceutical companies, coupled with a rising incidence of T-cell lymphoma cases globally, are contributing to this expanding market segment.

Regional Insights

North America leads the Global Non-Hodgkin Lymphoma Market due to its advanced healthcare infrastructure and substantial investment in research and development initiatives. The region benefits from a favorable regulatory environment, where bodies such as the U. S. Food and Drug Administration (FDA) facilitate accelerated pathways for novel therapeutic approvals, ensuring rapid access to innovative treatments. This, combined with high healthcare expenditure and a strong emphasis on adopting advanced medical technologies, including targeted therapies and immunotherapies, drives market expansion. Furthermore, a high level of patient awareness and a significant prevalence of Non-Hodgkin Lymphoma contribute to the demand for effective management solutions, solidifying North America's dominant position.

Recent Developments

• In December 2024, Roche presented new and updated clinical data for its CD20xCD3 bispecific antibodies, Columvi and Lunsumio, at the American Society of Hematology Annual Meeting. The data highlighted durable remissions achieved with fixed-duration treatment regimens for patients with lymphoma. Furthermore, a new subcutaneous formulation of Lunsumio demonstrated non-inferiority to intravenous administration, along with a consistent safety profile. These findings reinforce the potential of these therapies to improve outcomes and provide more convenient administration options for individuals with various B-cell non-Hodgkin lymphomas.

• In June 2024, Genmab, in collaboration with AbbVie, received FDA approval for epcoritamab-bysp (EPKINLY) for treating relapsed or refractory follicular lymphoma. EPKINLY is a T-cell engaging bispecific antibody, administered subcutaneously, and is designed to bind to both CD3 on T cells and CD20 on B cells, thereby inducing T cells to eliminate CD20-positive cancerous cells. This approval is notable as it introduces the first and only subcutaneous T-cell engaging bispecific antibody for this indication in the United States, offering a new treatment approach within the Non-Hodgkin Lymphoma Market.

• In May 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration granted approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy. This approval is for adult patients with relapsed or refractory mantle cell lymphoma who have undergone at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor. Breyanzi is now the only CAR T cell therapy approved for four distinct subtypes of non-Hodgkin lymphoma, expanding treatment possibilities for a broader range of B-cell malignancies.

• In March 2024, BeiGene's Bruton's tyrosine kinase (BTK) inhibitor, zanubrutinib (Brukinsa), received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma. This specific subtype of non-Hodgkin lymphoma arises from B cells. Zanubrutinib represents a significant advancement as the first BTK inhibitor approved for follicular lymphoma, addressing a critical need for new therapeutic options in patients who have received prior treatments. This approval marks a key expansion of treatment modalities within the global Non-Hodgkin Lymphoma Market.

Key Market Players

• AbbVie Inc
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Seagen, Inc (Pfizer Inc.)
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc
• Merck & Co. Inc

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-Hodgkin Lymphoma Market, By Disease Type:

o   B-cell Lymphomas

o   T-cell Lymphoma

• Non-Hodgkin Lymphoma Market, By Drug Class:

o   Monoclonal Antibodies

o   Antibody-Drug Conjugates

o   BTK/BCL-2 Kinase Inhibitors

o   PI3 Kinase Inhibitors

o   Others

• Non-Hodgkin Lymphoma Market, By Route of Administration:

o   Oral

o   Parenteral

o   Others

• Non-Hodgkin Lymphoma Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Others

• Non-Hodgkin Lymphoma Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma Market.

Available Customizations:

Global Non-Hodgkin Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Non-Hodgkin Lymphoma Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]